DAWN
Companies
NASDAQ
Day One Biopharmaceuticals, Inc.
Health Care
$6.41
-$6.26 (-49.41%)
Price Chart
Overview
About DAWN
Day One Biopharmaceuticals Inc is a clinical-stage biopharmaceutical company. It is dedicated towards developing and commercializing targeted therapies for patients of all ages with genetically defined cancers. Initially, it focuses on clinical development efforts on pediatric patients living with cancer, a vulnerable population that has been underserved in the recent revolution in targeted therapeutics and immuno-oncology. The product candidate, DAY101, is an oral, brain-penetrant, highly-selective type II pan-rapidly accelerated fibrosarcoma, or pan-RAF, kinase inhibitor.
Market Cap
$1.1B
Volume
12.3M
Avg. Volume
9.4M
P/E Ratio
-5.875
Dividend Yield
0.00%
Employees
137.0
Company Information
Risk & Correlation Analysis
Market Correlation
0.65
Low Correlation
Volatility
High (0.59)
Relative to market
Macro Factor Sensitivities
Interest Rates
Medium Sensitivity
Inflation
High Sensitivity
GDP Growth
Medium Sensitivity
Liquidity
Medium Sensitivity
Commodity Prices
High Sensitivity
Credit Quality
High Sensitivity
Portfolio Impact
Forecasts & Predictions
1-Month Target
$XXX.XX
+X.X% Potential
3-Month Target
$XXX.XX
+X.X% Potential
12-Month Target
$XXX.XX
+X.X% Potential
Technical Analysis
Based on technical indicators and chart patterns, DAWN shows...
AI Sentiment Analysis
Market sentiment analysis indicates...
Key Statistics
Market Cap$1.1B
Volume12.3M
P/E Ratio-5.88
Dividend Yield0.00%
Important Dates
Next Dividend
Next Earnings
February 26, 2025Related Securities
Pricing info last updated June 18, 2025 (after market close)Other info last updated April 2, 2025